{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:53:50Z","timestamp":1785887630753,"version":"3.56.0"},"reference-count":5,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.eururo.2026.02.004","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T03:41:38Z","timestamp":1778902898000},"page":"175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Re: Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Gu\u00e9rin (BCG) in BCG-na\u00efve High-risk Non\u2013muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials"],"prefix":"10.1016","volume":"90","author":[{"given":"Eva","family":"Comp\u00e9rat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2026.02.004_b0005","unstructured":"Gontero P, et al. EAU guidelines on non-muscle-invasive bladder cancer. Arnhem, The Netherlands: European Association of Urology; 2026."},{"key":"10.1016\/j.eururo.2026.02.004_b0010","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1038\/s41591-025-03738-z","article-title":"Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial","volume":"31","author":"Shore","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.eururo.2026.02.004_b0015","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1016\/S0140-6736(25)01897-5","article-title":"Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial","volume":"406","author":"De Santis","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2026.02.004_b0020","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.annonc.2025.09.017","article-title":"ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical bacillus Calmette-Guerin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC)","volume":"37","author":"Roupret","year":"2026","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2026.02.004_b0025","doi-asserted-by":"crossref","unstructured":"Scilipoti P, et al. Efficacy and safety of checkpoint inhibitors combined with bacillus Calmette-Gu\u00e9rin (BCG) in BCG-na\u00efve high-risk non\u2013muscle-invasive bladder cancer: synthesis of evidence from the ALBAN, CREST, and POTOMAC trials. Eur Urol. In press. https:\/\/doi.org\/10.1016\/j.eururo.2025.12.022.","DOI":"10.1016\/j.eururo.2025.12.022"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826019949?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826019949?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:26:32Z","timestamp":1785885992000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283826019949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":5,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0302283826019949"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2026.02.004","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Re: Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Gu\u00e9rin (BCG) in BCG-na\u00efve High-risk Non\u2013muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2026.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}